| Date |
Manual Section |
Type |
Description |
| 9/20/2018 |
2018: LYM Post-Infusion |
Add |
Added the following instruction for reporting pre-HCT lines of therapy: If this is a subsequent infusion and the 2018 was completed for the previous infusion, lines of therapy do not need to be reported in duplication on the subsequent 2018. Please report from post previous infusion to time of preparative regimen (or infusion) for the current HCT or cellular therapy. If no 2018 was completed previously, all lines of therapy from original diagnosis to current preparative regimen (or infusion) will have to be completed. |
| 9/20/2018 |
2118: LYM Post-Infusion Data |
Modify |
Changed the instruction for for reporting questions 88 and 89 by removing (strike through) and adding (red) text as indicated below. The center does not need to repeat all disease-specific assessments (biopsies, i.e., CT (radiographic) or PET scans, labs) each reporting period in order to complete current disease status data fields. Once a particular disease status is achieved, the center can continue reporting that disease status (based on labs / clinical assessments) until there is evidence of relapse / progression. If a disease-specific assessment did not occur during this time period, please report the date of any disease related assessment (e.g. clinical assessments, labs, etc.) as the date assessed (Q88 or Q90) regardless of what the parent question states about the specific CT (radiographic) or PET criteria. |
| 9/20/2018 |
2000: Recipient Baseline |
Modify |
Removed If the specific organism is not listed, use the "other, specify" code 209 - candida, 219 - apsergillus, or 259 - fungus and report the name of the organism in the space provided for question 59. Modified language to complete a Fungal Infection Form for all organisms. Removed the list of fungal organisms |
| 9/20/2018 |
2400: Pre-TED |
Add |
Added in text that mid-level health care providers (NPs and PAs) can also assign performance scores |
| 9/20/2018 |
2004: Infectious Disease Markers |
Add |
Added the following text "If testing is only performed on the harvested product and not on the peripheral blood sample, report those samples accordingly" |
| 8/10/2018 |
2450: Post-TED |
Modify |
Modified (added text in red and deleted text is struck-out) the instructions for reporting the "date assessed" for questions 80, 83, 87, 90, 96, and 96: If the best response is "not in complete remission," report the date of the most recent testing performed during the reporting period and prior to relapse or progression treatment for relapsed, progressive, or persistent disease, if applicable. If no treatment for relapsed, progressive, or persistent disease was given, report the date of the most recent disease-specific testing performed within approximately 30 days of the follow-up date. |
| 8/10/2018 |
2014: MDS/MPN Pre-HCT |
Add |
Added an instructional blue box for question 123: Myelofibrosis that develops in patients with essential thrombocythemia (ET) or polycythemia vera (PV) is considered secondary myelofibrosis. The CIBMTR forms capture disease subtype using the WHO classification of myeloid neoplasms and acute leukemia. Secondary myelofibrosis is not included as a separate category per the WHO classification. Therefore, when reporting the disease subtype at the time of transplant for recipients with secondary myelofibrosis, report "Primary Myelofibrosis (PMF)" to accurately capture these cases on the CIBMTR Forms. |
| 8/10/2018 |
2402: Disease Classification |
Modify |
Modified (red text was added, struck out text was deleted) the instructional blue box for question 212: Myelofibrosis that develops in patients with essential thrombocythemia (ET) or polycythemia vera (PV) is considered secondary myelofibrosis. The CIBMTR forms capture disease subtype using the WHO classification of myeloid neoplasms and acute leukemia. Secondary myelofibrosis is not included as a separate category per the WHO classification. Therefore, when reporting the disease subtype at the time of transplant for recipients with secondary myelofibrosis, report "Primary Myelofibrosis (PMF)" to accurately capture these cases on the CIBMTR Forms. Myelofibrosis that develops in patients with essential thrombocythemia (ET) or polycythemia vera (PV) is considered secondary myelofibrosis. However, effective immediately, cases of post-essential thrombocythemia myelofibrosis (post-ET MF) or post-polycythemia vera myelofibrosis (post-PV MF) will now be reported as "Primary Myelofibrosis (PMF)" at the time of HCT. In order to capture accurate data, the secondary MF cases need to be lumped in with the PMF cases, since treatment for post-ET MF and post-PV MF is the same as PMF. |
| 8/10/2018 |
2010: AML Pre-Infusion |
Add |
Added the following instruction for questions 72 - 74: If a differential was performed and there were no blasts present in the peripheral blood, the laboratory report may not display a column for blasts. In this case, it can be assumed that no blasts were present and "0" can be reported on the form. |
| 8/10/2018 |
2450: Post-TED |
Remove |
Removed the following instruction from questions 157 and 231: Reporting the administration of a cellular therapy / donor cellular infusion in question 231 will generate additional cellular therapy forms which are used to capture important details regarding the infusion(s).
|
| 8/10/2018 |
2018: LYM Pre-Infusion |
Add |
Added instruction for question 217: If the recipient had palpable disease on a physical exam, those results can be reported in the CT (radiographic) criteria. |
| 8/9/2018 |
2402: Disease Classification |
Add |
Added instruction for question 281-282: If the PET scan result is only documented as an 'X', report this as "Unknown" for question 281. |
